High bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis

Koji Ishikawa,1–3 Takashi Nagai,1 Koki Tsuchiya,1 Yusuke Oshita,3 Takuma Kuroda,1 Hiroshi Ito,1 Soji Tani,1 Yusuke Dodo,1 Tomoaki Toyone,1 Katsunori Inagaki1 1Department of Orthopaedic Surgery, Showa University School of Medicine, Tokyo, Japan; 2Department of Orthopaedic and Spine Surgery...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ishikawa K, Nagai T, Tsuchiya K, Oshita Y, Kuroda T, Ito H, Tani S, Dodo Y, Toyone T, Inagaki K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Denosumab Symptomatic hypocalcemia High bone turnover No renal impairment Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/19c9bed2c2ce45dd91f6fa463635bb72
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:19c9bed2c2ce45dd91f6fa463635bb72
record_format	dspace
spelling	oai:doaj.org-article:19c9bed2c2ce45dd91f6fa463635bb722021-12-02T04:39:46ZHigh bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis1178-1998https://doaj.org/article/19c9bed2c2ce45dd91f6fa463635bb722018-10-01T00:00:00Zhttps://www.dovepress.com/high-bone-turnover-status-as-a-risk-factor-in-symptomatic-hypocalcemia-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Koji Ishikawa,1–3 Takashi Nagai,1 Koki Tsuchiya,1 Yusuke Oshita,3 Takuma Kuroda,1 Hiroshi Ito,1 Soji Tani,1 Yusuke Dodo,1 Tomoaki Toyone,1 Katsunori Inagaki1 1Department of Orthopaedic Surgery, Showa University School of Medicine, Tokyo, Japan; 2Department of Orthopaedic and Spine Surgery, Sanraku Hospital, Tokyo, Japan; 3Department of Orthopaedic Surgery, Yamanashi Red Cross Hospital, Yamanashi, Japan Abstract: Denosumab is a fully human monoclonal antibody against the receptor activator of nuclear factor-κB ligand (RANKL) that is used for the treatment of osteoporosis. Denosumab-induced hypocalcemia is a rare but important adverse event, which is usually asymptomatic in patients with osteoporosis. It is also known that hypocalcemia is common in patients with bone metastases and severe renal impairment. Here we report a case of symptomatic hypocalcemia following administration of 60 mg of denosumab in a patient with high bone turnover and no renal impairment (estimated glomerular filtration rate [eGFR], 71 mL/min), despite prophylactic oral vitamin D administration. This report supports our observation that there is a risk of protracted and marked denosumab-induced hypocalcemia in patients with high bone turnover, irrespective of their degree of renal impairment. Keywords: denosumab, symptomatic hypocalcemia, high bone turnover, no renal impairmentIshikawa KNagai TTsuchiya KOshita YKuroda TIto HTani SDodo YToyone TInagaki KDove Medical PressarticleDenosumabSymptomatic hypocalcemiaHigh bone turnoverNo renal impairmentGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 13, Pp 1929-1934 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Denosumab Symptomatic hypocalcemia High bone turnover No renal impairment Geriatrics RC952-954.6
spellingShingle	Denosumab Symptomatic hypocalcemia High bone turnover No renal impairment Geriatrics RC952-954.6 Ishikawa K Nagai T Tsuchiya K Oshita Y Kuroda T Ito H Tani S Dodo Y Toyone T Inagaki K High bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis
description	Koji Ishikawa,1–3 Takashi Nagai,1 Koki Tsuchiya,1 Yusuke Oshita,3 Takuma Kuroda,1 Hiroshi Ito,1 Soji Tani,1 Yusuke Dodo,1 Tomoaki Toyone,1 Katsunori Inagaki1 1Department of Orthopaedic Surgery, Showa University School of Medicine, Tokyo, Japan; 2Department of Orthopaedic and Spine Surgery, Sanraku Hospital, Tokyo, Japan; 3Department of Orthopaedic Surgery, Yamanashi Red Cross Hospital, Yamanashi, Japan Abstract: Denosumab is a fully human monoclonal antibody against the receptor activator of nuclear factor-κB ligand (RANKL) that is used for the treatment of osteoporosis. Denosumab-induced hypocalcemia is a rare but important adverse event, which is usually asymptomatic in patients with osteoporosis. It is also known that hypocalcemia is common in patients with bone metastases and severe renal impairment. Here we report a case of symptomatic hypocalcemia following administration of 60 mg of denosumab in a patient with high bone turnover and no renal impairment (estimated glomerular filtration rate [eGFR], 71 mL/min), despite prophylactic oral vitamin D administration. This report supports our observation that there is a risk of protracted and marked denosumab-induced hypocalcemia in patients with high bone turnover, irrespective of their degree of renal impairment. Keywords: denosumab, symptomatic hypocalcemia, high bone turnover, no renal impairment
format	article
author	Ishikawa K Nagai T Tsuchiya K Oshita Y Kuroda T Ito H Tani S Dodo Y Toyone T Inagaki K
author_facet	Ishikawa K Nagai T Tsuchiya K Oshita Y Kuroda T Ito H Tani S Dodo Y Toyone T Inagaki K
author_sort	Ishikawa K
title	High bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis
title_short	High bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis
title_full	High bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis
title_fullStr	High bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis
title_full_unstemmed	High bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis
title_sort	high bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/19c9bed2c2ce45dd91f6fa463635bb72
work_keys_str_mv	AT ishikawak highboneturnoverstatusasariskfactorinsymptomatichypocalcemiafollowingdenosumabtreatmentinamalepatientwithosteoporosis AT nagait highboneturnoverstatusasariskfactorinsymptomatichypocalcemiafollowingdenosumabtreatmentinamalepatientwithosteoporosis AT tsuchiyak highboneturnoverstatusasariskfactorinsymptomatichypocalcemiafollowingdenosumabtreatmentinamalepatientwithosteoporosis AT oshitay highboneturnoverstatusasariskfactorinsymptomatichypocalcemiafollowingdenosumabtreatmentinamalepatientwithosteoporosis AT kurodat highboneturnoverstatusasariskfactorinsymptomatichypocalcemiafollowingdenosumabtreatmentinamalepatientwithosteoporosis AT itoh highboneturnoverstatusasariskfactorinsymptomatichypocalcemiafollowingdenosumabtreatmentinamalepatientwithosteoporosis AT tanis highboneturnoverstatusasariskfactorinsymptomatichypocalcemiafollowingdenosumabtreatmentinamalepatientwithosteoporosis AT dodoy highboneturnoverstatusasariskfactorinsymptomatichypocalcemiafollowingdenosumabtreatmentinamalepatientwithosteoporosis AT toyonet highboneturnoverstatusasariskfactorinsymptomatichypocalcemiafollowingdenosumabtreatmentinamalepatientwithosteoporosis AT inagakik highboneturnoverstatusasariskfactorinsymptomatichypocalcemiafollowingdenosumabtreatmentinamalepatientwithosteoporosis
_version_	1718401112428511232

High bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis

Ejemplares similares